Evaluation of IL-34 in psoriasis and psoriatic arthritis patients: Correlation with disease activity and severity
Evaluation of IL-34 in psoriasis and psoriatic arthritis patients: Correlation with disease activity and severity
复制标题
DOI：
10.1016/j.ejr.2016.05.008
复制
发表时间：
2017-01-01
影响因子：
0.9
通讯作者：
Ghobrial, Christine K.
中科院分区：
文献类型：
--
作者：
Farrag, Dina A.;Asaad, Marwa K.;Ghobrial, Christine K.
前言：白介素34(IL-34)是新近发现的一种皮肤内稳态所必需的细胞因子。它参与巨噬细胞分化、破骨细胞形成和炎症。目的：探讨银屑病患者血清IL-34水平与银屑病活动度、病情严重程度的相关性。方法：检测45例银屑病患者(21例PSA)和20例健康对照血清IL-34水平。采用银屑病皮肤面积严重指数(PASI)、综合银屑病疾病活动指数(CPDAI)和周围关节评分(PJS)对患者进行临床评估。结果：PSA患者的平均年龄(47.4±10.2岁)与单纯银屑病患者(42.5±7.5岁)和对照组(43.4±7岁)相当。PSA组血清IL-34水平显著高于非关节炎组和对照组(中位数分别为2500 ng/L、512 ng/L和325 ng/L)。与非关节炎患者相比，PSA患者的CPDAI显著升高。PASI评分在患者之间具有可比性。血清IL-34水平与PASI、CPDAI、PJS呈显著正相关，与mSvH评分无相关性。受试者特征曲线分析显示，血清IL-34检测对银屑病患者PSA具有良好的诊断性能。结论：PSA患者血清IL-34水平明显高于非关节炎患者，且与PSA疾病活动性显著相关，提示其作为银屑病患者关节炎的标志物具有重要意义。(C)2016年埃及风湿病学会。爱思唯尔B.V.提供的出版服务。这是CC BY-NC-ND许可证(http://creativecommons.org/licenses/by-nc-nd/4.0/).下的一篇开放获取文章
Introduction: Interleukin-34 (IL-34) is a newly discovered cytokine essential for skin homoeostasis. It is involved in macrophage differentiation, osteoclastogenesis and inflammation. This could suggest a potential role in the pathogenesis of psoriasis and psoriatic arthritis (PsA).Aim of the work: To assess serum IL-34 level in psoriatic patients with and without arthritis and to correlate it with disease activity and severity.Patients and methods: Serum IL-34 level was measured in 45 psoriasis patients (21 had PsA) and 20 healthy controls. Patients were clinically assessed using psoriasis skin area severity index (PASI), composite psoriasis disease activity index (CPDAI) and peripheral joint score (PJS). Radiological assessment of hands and feet was done using modified Sharp-van der Heijde (mSvH) scoring method for PsA.Results: The mean age of the PsA patients (47.4 +/- 10.2 years) was comparable with the psoriasis only patients (42.5 +/- 7.5 years) and control (43.4 +/- 7 years). Serum IL-34 was significantly higher among PsA patients compared to those without arthritis and controls (median = 2500 ng/L, 512 ng/L and 325 ng/L, respectively). CPDAI was significantly higher in PsA compared to patients without arthritis. PASI scores were comparable between patients. Serum IL-34 level correlated significantly with each of PASI, CPDAI and PJS but not with the mSvH score. Receiver operator characteristic curve analysis revealed that serum IL-34 testing showed excellent diagnostic performance for PsA in psoriasis patients.Conclusion: The markedly elevated IL-34 serum level in PsA patients compared to non-arthritic ones and its remarkable correlation with PsA disease activity, suggest its importance as a marker for arthritis in psoriasis patients. (C) 2016 Egyptian Society of Rheumatic Diseases. Publishing services provided by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).